دورية أكاديمية
Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children's Leukemia Group.
| العنوان: | Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children's Leukemia Group. |
|---|---|
| المؤلفون: | Qiu KY; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Xu HG; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Luo XQ; Department of Paediatrics, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China., Mai HR; Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China., Liao N; Department of Paediatrics, Guangxi Medical University First Affiliated Hospital, Nanning, China., Yang LH; Department of Paediatrics, Southern Medical University Zhujiang Hospital, Guangzhou, China., Zheng MC; Department of Hematology, Hunan Children's Hospital, Changsha, China., Wan WQ; Department of Paediatrics, Second Xiangya Hospital of Central South University, Changsha, China., Wu XD; Department of Paediatrics, Southern Medical University Nanfang Hospital, Guangzhou, China., Liu RY; Department of Paediatrics, Huizhou Central People's Hospital, Huizhou, China., Chen QW; Department of Paediatrics, First Affiliated Hospital of Nanchang University, Nanchang, China., Chen HQ; Department of Paediatrics, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Sun XF; Department of Paediatrics, Sun Yat-sen University Cancer Center, Guangzhou, China., Jiang H; Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou, China., Long XJ; Department of Paediatrics, Liuzhou People's Hospital, Liuzhou, China., Chen GH; Department of Paediatrics, Huizhou First People's Hospital, HuiZhou, China., Li XY; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Li CG; Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China., Huang LB; Department of Paediatrics, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China., Ling YY; Department of Paediatrics, Guangxi Medical University First Affiliated Hospital, Nanning, China., Lin DN; Department of Paediatrics, Southern Medical University Zhujiang Hospital, Guangzhou, China., Wen C; Department of Paediatrics, Second Xiangya Hospital of Central South University, Changsha, China., Kuang WY; Department of Hematology, Hunan Children's Hospital, Changsha, China., Feng XQ; Department of Paediatrics, Southern Medical University Nanfang Hospital, Guangzhou, China., Ye ZL; Department of Paediatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China., Wu BY; Department of Paediatrics, The First Affiliated Hospital of Shantou University Medical College, Shantou, China., He XL; Department of Paediatrics, Hunan Provincial People's Hospital, Changsha, China., Li QR; Department of Paediatrics, Zhongshan People's Hospital, Zhongshan, China., Wang LN; Department of Paediatrics, Guangzhou First People's Hospital, Guangzhou, China., Kong XL; Department of Paediatrics, Boai Hospital of Zhongshan, Zhongshan, China., Xu LH; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Li CK; Department of Paediatrics, Hong Kong Children Hospital and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China., Fang JP; Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. |
| المصدر: | Frontiers in oncology [Front Oncol] 2021 Dec 20; Vol. 11, pp. 797194. Date of Electronic Publication: 2021 Dec 20 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Purpose: To analyzed the outcome of ETV6/RUNX1-positive pediatric acute B lymphoblastic leukemia (B-ALL) with the aim of identifying prognostic value. Method: A total of 2,530 pediatric patients who were diagnosed with B-ALL were classified into two groups based on the ETV6/RUNX1 status by using a retrospective cohort study method from February 28, 2008, to June 30, 2020, at 22 participating ALL centers. Results: In total, 461 (18.2%) cases were ETV6/RUNX1-positive. The proportion of patients with risk factors (age <1 year or ≥10 years, WB≥50×10 9 /L) in ETV6/RUNX1-positive group was significantly lower than that in negative group ( P <0.001), while the proportion of patients with good early response (good response to prednisone, D15 MRD < 0.1%, and D33 MRD < 0.01%) in ETV6/RUNX1-positive group was higher than that in the negative group ( P <0.001, 0.788 and 0.004, respectively). Multivariate analysis of 2,530 patients found that age <1 or ≥10 years, SCCLG-ALL-2016 protocol, and MLL were independent predictor of outcome but not ETV6/RUNX1. The EFS and OS of the ETV6/RUNX1-positive group were significantly higher than those of the negative group (3-year EFS: 90.11 ± 4.21% vs 82 ± 2.36%, P <0.0001, 3-year OS: 91.99 ± 3.92% vs 88.79 ± 1.87%, P =0.017). Subgroup analysis showed that chemotherapy protocol, age, prednisone response, and D15 MRD were important factors affecting the prognosis of ETV6/RUNX1-positive children. Conclusions: ETV6/RUNX1-positive pediatric ALL showed an excellent outcome but lack of independent prognostic significance in South China. However, for older patients who have the ETV6/RUNX1 fusion and slow response to therapy, to opt for more intensive treatment. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Qiu, Xu, Luo, Mai, Liao, Yang, Zheng, Wan, Wu, Liu, Chen, Chen, Sun, Jiang, Long, Chen, Li, Li, Huang, Ling, Lin, Wen, Kuang, Feng, Ye, Wu, He, Li, Wang, Kong, Xu, Li and Fang.) |
| References: | Am J Hematol. 2012 Nov;87(11):1022-7. (PMID: 22911440) Cancer Genet. 2016 Jul-Aug;209(7-8):340-7. (PMID: 27341996) J Clin Oncol. 2008 May 1;26(13):2186-91. (PMID: 18445843) Blood. 2001 Aug 1;98(3):558-64. (PMID: 11468150) J Clin Oncol. 2020 Feb 20;38(6):602-612. (PMID: 31825704) Mol Oncol. 2012 Oct;6(5):553-64. (PMID: 22846743) Lancet. 2013 Jun 1;381(9881):1943-55. (PMID: 23523389) Indian J Hematol Blood Transfus. 2016 Jun;32(2):154-61. (PMID: 27065576) Iran J Pediatr. 2013 Dec;23(6):681-6. (PMID: 24910748) Environ Res. 2020 Mar;182:109023. (PMID: 31911233) Blood. 2000 Aug 1;96(3):1094-9. (PMID: 10910927) Int J Hematol. 2019 Apr;109(4):477-482. (PMID: 30689137) Front Oncol. 2020 Jun 30;10:923. (PMID: 32695667) Lancet Oncol. 2019 Mar;20(3):e142-e154. (PMID: 30842058) J Pediatr Hematol Oncol. 2009 Dec;31(12):930-5. (PMID: 19875970) Diagn Pathol. 2016 Sep 15;11(1):89. (PMID: 27632978) J Clin Oncol. 2016 Jul 10;34(20):2380-8. (PMID: 27114587) Pediatr Clin North Am. 2015 Feb;62(1):47-60. (PMID: 25435111) Int J Hematol. 2021 Apr;113(4):547-555. (PMID: 33386596) Int J Oncol. 1998 Dec;13(6):1319-22. (PMID: 9824651) Leukemia. 2012 Feb;26(2):265-70. (PMID: 21869842) BMC Cancer. 2021 Jan 13;21(1):59. (PMID: 33435902) Leukemia. 2017 Feb;31(2):333-339. (PMID: 27560110) Mol Cancer Res. 2004 Jun;2(6):339-47. (PMID: 15235109) Cancer Res Treat. 2017 Apr;49(2):446-453. (PMID: 27506214) Blood. 2004 Oct 15;104(8):2452-7. (PMID: 15217836) Cancer. 1998 Apr 1;82(7):1387-95. (PMID: 9529033) Br J Haematol. 2008 Mar;140(6):665-72. (PMID: 18241254) Leukemia. 2018 Jan;32(1):244-248. (PMID: 29064485) Int J Lab Hematol. 2017 Apr;39(2):121-128. (PMID: 28004528) Cancer Genet. 2018 Aug;224-225:1-11. (PMID: 29778230) BMC Cancer. 2021 Jul 15;21(1):813. (PMID: 34266412) Blood. 2006 Jun 1;107(11):4508-13. (PMID: 16493009) Cancer. 2015 Oct 15;121(20):3577-90. (PMID: 26194091) Blood Adv. 2019 Nov 26;3(22):3688-3699. (PMID: 31765480) J Clin Oncol. 2018 Oct 10;36(29):2926-2934. (PMID: 30138085) Am J Hematol. 2018 Jul;93(7):913-920. (PMID: 29675840) Cancer Res Treat. 2021 Apr;53(2):567-575. (PMID: 33070555) Leukemia. 2013 Nov;27(11):2165-76. (PMID: 23628958) |
| فهرسة مساهمة: | Keywords: ETV6/RUNX1; acute B lymphoblastic leukemia; multicenter cohort study; outcome; prognosis |
| تواريخ الأحداث: | Date Created: 20220106 Latest Revision: 20220429 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC8722219 |
| DOI: | 10.3389/fonc.2021.797194 |
| PMID: | 34988026 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2021.797194 |